Autologous Stem Cell Gene Editing for Corneal Dystrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for corneal dystrophies, such as granular corneal dystrophy type II and keratoconus, are limited by the availability of donor corneal tissues and the recurrence of disease in transplanted grafts, along with complications like scarring and vision problems, necessitating alternative therapeutic approaches.
Innovation Solution
A method involving the manipulation of nucleic acid mutations in stem cells to correct genetic defects associated with corneal dystrophies, using CRISPR/nuclease systems to introduce guide RNAs and nucleases that correct specific mutations in TGFBI and other target genes, followed by transplantation of these modified stem cells to treat the condition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If corneal transplantation is performed to treat corneal dystrophies, then visual impairment is improved, but the availability of donor corneal tissues is limited and disease recurrence in grafts occurs
Solution Approach 1:
The patent uses gene therapy to create a functional copy of the normal TGFBI gene in the patient's own stem cells, replacing the defective mutant gene. This molecular copying approach allows unlimited production of healthy corneal tissue from the patient's stem cells, eliminating the need for scarce donor corneal tissues while maintaining treatment effectiveness.
Solution Approach 2:
The patent employs autologous stem cell therapy where the patient's own stem cells are genetically modified to produce functional TGFBI protein. This self-service approach uses the patient's biological material to treat their own condition, eliminating dependence on external donor tissues and reducing the risk of disease recurrence in grafts.
2Reliability
If corneal transplantation is performed to treat corneal dystrophies, then visual impairment is improved, but complications like scarring and vision problems occur
Solution Approach 1:
The patent performs preliminary genetic correction of the TGFBI gene in stem cells before transplantation. By correcting the genetic defect in advance and using the patient's own stem cells to generate healthy corneal tissue, the treatment prevents disease recurrence and minimizes scarring complications that typically occur with conventional corneal transplantation.
3Ease of manufacture
If conventional treatments are used for corneal dystrophies, then the treatment approach is simple, but the duration of therapeutic effect is limited due to disease progression
Solution Approach 1:
The patent replaces conventional mechanical/surgical treatments (corneal transplantation) with a molecular biology approach using gene therapy. By introducing functional TGFBI gene copies into stem cells, the treatment addresses the root genetic cause of the disease, providing long-lasting or potentially curative effects rather than temporary symptom management.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach potentially offers a durable solution by correcting the genetic basis of corneal dystrophies, reducing protein deposition and improving visual acuity, with the potential for repeated transplantation to maintain therapeutic effects.
Implementation Method 1
using CRISPR/nuclease systems to introduce guide RNAs and nucleases that correct specific mutations in TGFBI and other target genes
Implementation Method 2
manipulating a nucleic acid mutation in a corneal dystrophy target nucleic acid in a stem cell from the subject to correct the nucleic acid mutation
Data Source
AI summary
Methods and compositions for the treatment of a corneal dystrophy in a subject in need thereof are provided. In one aspect, the method includes the step of obtaining a plurality of stem cells comprising a nucleic acid mutation in a corneal dystrophy target nucleic acid from the subject and manipulating the nucleic acid mutation in one or more stem cells of the plurality of stem cells to correct the nucleic acid mutation, thereby forming one or more manipulated stem cells. The manipulated stem cells are isolated and then transplanted into the subject. In some embodiments, the nucleic acid mutation is manipulated using CRISPR system.